用八珍草和薏苡仁靶向治疗结直肠癌:网络药理学、分子对接和体外验证。

IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Cheng-Lei Wang, Bing-Wei Yang, Xin-Yan Wang, Xue Chen, Wei-Dong Li, Hao-Yu Zhai, Ying Wu, Mu-Yao Cui, Jia-He Wu, Qing-Hui Meng, Nan Zhang
{"title":"用八珍草和薏苡仁靶向治疗结直肠癌:网络药理学、分子对接和体外验证。","authors":"Cheng-Lei Wang, Bing-Wei Yang, Xin-Yan Wang, Xue Chen, Wei-Dong Li, Hao-Yu Zhai, Ying Wu, Mu-Yao Cui, Jia-He Wu, Qing-Hui Meng, Nan Zhang","doi":"10.4251/wjgo.v16.i8.3539","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Herba Patriniae and Coix seed (HC) constitute a widely utilized drug combination in the clinical management of colorectal cancer (CRC) that is known for its diuretic, anti-inflammatory, and swelling-reducing properties. Although its efficacy has been demonstrated in a clinical setting, the active compounds and their mechanisms of action in CRC treatment remain to be fully elucidated.</p><p><strong>Aim: </strong>To identify the active, CRC-targeting components of HC and to elucidate the mechanisms of action involved.</p><p><strong>Methods: </strong>Active HC components were identified and screened using databases. Targets for each component were predicted. CRC-related targets were obtained from human gene databases. Interaction targets between HC and CRC were identified. A \"drug-ingredient-target\" network was created to identify the core components and targets involved. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the key pathways involved. Molecular docking between core targets and key components was executed. <i>In vitro</i> experiments validated core monomers.</p><p><strong>Results: </strong>Nineteen active components of HC were identified, with acacetin as the primary active compound. The predictive analysis identified 454 targets of the active compounds in HC. Intersection mapping with 2685 CRC-related targets yielded 171 intervention targets, including 30 core targets. GO and KEGG analyses indicated that HC may influence the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. Molecular docking showed that acacetin exhibited an optimal interaction with <i>AKT1</i>, identifying <i>PI3K</i>, <i>AKT</i>, and <i>P53</i> as key genes likely targeted by HC during CRC treatment. Acacetin inhibited HT-29 cell proliferation and migration, as well as promoted apoptosis, <i>in vitro</i>. Western blotting analysis revealed increased <i>p53</i> and cleaved caspase-3 expression and decreased levels of <i>p-PI3K</i>, <i>p-Akt</i>, and survivin, which likely contributed to CRC apoptosis.</p><p><strong>Conclusion: </strong>Acacetin, the principal active compound in the HC pair, inhibited the proliferation and migration of HT-29 cells and promoted apoptosis through the PI3K/Akt/p53 signaling pathway.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334031/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting colorectal cancer with Herba Patriniae and Coix seed: Network pharmacology, molecular docking, and <i>in vitro</i> validation.\",\"authors\":\"Cheng-Lei Wang, Bing-Wei Yang, Xin-Yan Wang, Xue Chen, Wei-Dong Li, Hao-Yu Zhai, Ying Wu, Mu-Yao Cui, Jia-He Wu, Qing-Hui Meng, Nan Zhang\",\"doi\":\"10.4251/wjgo.v16.i8.3539\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Herba Patriniae and Coix seed (HC) constitute a widely utilized drug combination in the clinical management of colorectal cancer (CRC) that is known for its diuretic, anti-inflammatory, and swelling-reducing properties. Although its efficacy has been demonstrated in a clinical setting, the active compounds and their mechanisms of action in CRC treatment remain to be fully elucidated.</p><p><strong>Aim: </strong>To identify the active, CRC-targeting components of HC and to elucidate the mechanisms of action involved.</p><p><strong>Methods: </strong>Active HC components were identified and screened using databases. Targets for each component were predicted. CRC-related targets were obtained from human gene databases. Interaction targets between HC and CRC were identified. A \\\"drug-ingredient-target\\\" network was created to identify the core components and targets involved. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the key pathways involved. Molecular docking between core targets and key components was executed. <i>In vitro</i> experiments validated core monomers.</p><p><strong>Results: </strong>Nineteen active components of HC were identified, with acacetin as the primary active compound. The predictive analysis identified 454 targets of the active compounds in HC. Intersection mapping with 2685 CRC-related targets yielded 171 intervention targets, including 30 core targets. GO and KEGG analyses indicated that HC may influence the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. Molecular docking showed that acacetin exhibited an optimal interaction with <i>AKT1</i>, identifying <i>PI3K</i>, <i>AKT</i>, and <i>P53</i> as key genes likely targeted by HC during CRC treatment. Acacetin inhibited HT-29 cell proliferation and migration, as well as promoted apoptosis, <i>in vitro</i>. Western blotting analysis revealed increased <i>p53</i> and cleaved caspase-3 expression and decreased levels of <i>p-PI3K</i>, <i>p-Akt</i>, and survivin, which likely contributed to CRC apoptosis.</p><p><strong>Conclusion: </strong>Acacetin, the principal active compound in the HC pair, inhibited the proliferation and migration of HT-29 cells and promoted apoptosis through the PI3K/Akt/p53 signaling pathway.</p>\",\"PeriodicalId\":23762,\"journal\":{\"name\":\"World Journal of Gastrointestinal Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334031/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Gastrointestinal Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4251/wjgo.v16.i8.3539\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v16.i8.3539","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:八珍草和薏苡仁(HC)是临床上治疗结直肠癌(CRC)的一种广泛使用的复方药物,具有利尿、抗炎和消肿的功效。尽管其疗效已在临床环境中得到证实,但其活性化合物及其在 CRC 治疗中的作用机制仍有待全面阐明。目的:确定 HC 中针对 CRC 的活性成分,并阐明其中的作用机制:方法:利用数据库确定并筛选 HC 的活性成分。方法:利用数据库确定并筛选 HC 的活性成分,预测每种成分的靶点。与 CRC 相关的靶点来自人类基因数据库。确定了 HC 与 CRC 之间的相互作用靶点。创建了一个 "药物-成分-靶点 "网络,以确定所涉及的核心成分和靶点。进行基因本体(GO)和京都基因组百科全书(KEGG)分析,以阐明所涉及的关键通路。在核心靶标和关键成分之间进行了分子对接。体外实验验证了核心单体:结果:确定了 19 种 HC 活性成分,其中醋氨醇是主要的活性化合物。预测分析确定了 HC 中活性化合物的 454 个靶点。与 2685 个 CRC 相关靶点的交叉图谱得出了 171 个干预靶点,其中包括 30 个核心靶点。GO和KEGG分析表明,HC可能会影响磷酸肌酸3-激酶(PI3K)/Akt信号通路。分子对接显示,阿卡西汀与AKT1表现出最佳的相互作用,从而确定PI3K、AKT和P53是HC在治疗CRC过程中可能靶向的关键基因。阿卡西汀在体外抑制了 HT-29 细胞的增殖和迁移,并促进了细胞凋亡。Western印迹分析显示,p53和裂解的caspase-3表达增加,p-PI3K、p-Akt和survivin水平降低,这可能有助于CRC细胞凋亡:结论:HC 对中的主要活性化合物 Acacetin 可抑制 HT-29 细胞的增殖和迁移,并通过 PI3K/Akt/p53 信号通路促进细胞凋亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Targeting colorectal cancer with Herba Patriniae and Coix seed: Network pharmacology, molecular docking, and in vitro validation.

Background: Herba Patriniae and Coix seed (HC) constitute a widely utilized drug combination in the clinical management of colorectal cancer (CRC) that is known for its diuretic, anti-inflammatory, and swelling-reducing properties. Although its efficacy has been demonstrated in a clinical setting, the active compounds and their mechanisms of action in CRC treatment remain to be fully elucidated.

Aim: To identify the active, CRC-targeting components of HC and to elucidate the mechanisms of action involved.

Methods: Active HC components were identified and screened using databases. Targets for each component were predicted. CRC-related targets were obtained from human gene databases. Interaction targets between HC and CRC were identified. A "drug-ingredient-target" network was created to identify the core components and targets involved. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the key pathways involved. Molecular docking between core targets and key components was executed. In vitro experiments validated core monomers.

Results: Nineteen active components of HC were identified, with acacetin as the primary active compound. The predictive analysis identified 454 targets of the active compounds in HC. Intersection mapping with 2685 CRC-related targets yielded 171 intervention targets, including 30 core targets. GO and KEGG analyses indicated that HC may influence the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. Molecular docking showed that acacetin exhibited an optimal interaction with AKT1, identifying PI3K, AKT, and P53 as key genes likely targeted by HC during CRC treatment. Acacetin inhibited HT-29 cell proliferation and migration, as well as promoted apoptosis, in vitro. Western blotting analysis revealed increased p53 and cleaved caspase-3 expression and decreased levels of p-PI3K, p-Akt, and survivin, which likely contributed to CRC apoptosis.

Conclusion: Acacetin, the principal active compound in the HC pair, inhibited the proliferation and migration of HT-29 cells and promoted apoptosis through the PI3K/Akt/p53 signaling pathway.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Oncology Medicine-Gastroenterology
CiteScore
4.20
自引率
3.30%
发文量
1082
期刊介绍: The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信